Angliana Chouw
Research Subjects
Research Interests
Angliana Chouw has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
C.R. Sartika
12 shared publicationsY. Dirgantara
12 shared publications- Ferry Sandra
Department of Biochemistry and Molecular Biology, Division of Oral Biology, Faculty of Dentistry, Universitas Trisakti, Jakarta, Indonesia
10 shared publications J. Riswandani
7 shared publicationsCynthia Retna Sartika
Prodia StemCell Indonesia, Jakarta Pusat, Indonesia
6 shared publicationsE.D. Pratiwi
6 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Brazilian Archives of Biology and Technology
- Vol. 68, e25240110
Histone Potentiates Inositol Hexakisphosphate in Inducing Apoptosis of HONE-1 Nasopharyngeal Cancer Cells
Inositol hexakisphosphate (InsP6) requires relatively high concentrations to induce apoptosis of cancer cells, which can possibly cause apoptosis of normal cells. Anticancer ability of InsP6 could be preserved by combining with histone, so InsP6 can be used at low concentrations. The effect of InsP6 and histone combination has not been investigated on nasopharyngeal cancer cells. The current study elucidated the effect of InsP6 and its combination with histone on the apoptosis of HONE-1 cells. The most effective concentration and the cellular mechanisms by which this combination exerts its anticancer effects were also investigated. HONE-1 and NIH3T3 cells (as normal control cells) were treated with InsP6 and/or histone in different concentrations. Apoptosis percentages of the treated cells were measured with sub-G1 assay. Nuclear fragmentation and mitochondrial membrane potential (∆Ψm) reduction in the treated HONE-1 cells were confirmed with 4',6-diamidino-2-phenylindole (DAPI) staining and ∆Ψm assay, respectively. The combination of 10 μM InsP6 and 10 μg/mL histone had the optimal ability to induce the apoptosis of HONE-1 cells. This combination did not induce apoptosis of NIH3T3 cells. The apoptosis-inducing ability of this combination was higher than that of 10 μM InsP6 merely. The ability of InsP6 to induce apoptosis of HONE-1 cells could be enhanced by histone application. Combination of 10 μM InsP6 and 10 μg/mL histone might be the optimal concentrations for inducing apoptosis in HONE-1 cells.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Brazilian Archives of Biology and Technology
- Vol. 68, e25240110
Open AccessHistone Potentiates Inositol Hexakisphosphate in Inducing Apoptosis of HONE-1 Nasopharyngeal Cancer Cells
Inositol hexakisphosphate (InsP6) requires relatively high concentrations to induce apoptosis of cancer cells, which can possibly cause apoptosis of normal cells. Anticancer ability of InsP6 could be preserved by combining with histone, so InsP6 can be used at low concentrations. The effect of InsP6 and histone combination has not been investigated on nasopharyngeal cancer cells. The current study elucidated the effect of InsP6 and its combination with histone on the apoptosis of HONE-1 cells. The most effective concentration and the cellular mechanisms by which this combination exerts its anticancer effects were also investigated. HONE-1 and NIH3T3 cells (as normal control cells) were treated with InsP6 and/or histone in different concentrations. Apoptosis percentages of the treated cells were measured with sub-G1 assay. Nuclear fragmentation and mitochondrial membrane potential (∆Ψm) reduction in the treated HONE-1 cells were confirmed with 4',6-diamidino-2-phenylindole (DAPI) staining and ∆Ψm assay, respectively. The combination of 10 μM InsP6 and 10 μg/mL histone had the optimal ability to induce the apoptosis of HONE-1 cells. This combination did not induce apoptosis of NIH3T3 cells. The apoptosis-inducing ability of this combination was higher than that of 10 μM InsP6 merely. The ability of InsP6 to induce apoptosis of HONE-1 cells could be enhanced by histone application. Combination of 10 μM InsP6 and 10 μg/mL histone might be the optimal concentrations for inducing apoptosis in HONE-1 cells.
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Brazilian Oral Research
- Vol. 38, e037
Inhibition of lipopolysaccharide-induced NF-κB maintains osteogenesis of dental pulp and periodontal ligament stem cells
Dental pulp stem cells (DPSCs) and periodontal ligament stem cells (PDLSCs) can differentiate into osteoblasts, indicating that both are potential candidates for bone tissue engineering. Osteogenesis is influenced by many environmental factors, one of which is lipopolysaccharide (LPS). LPS-induced NF-κB activity affects the osteogenic potencies of different types of MSCs differently. This study evaluated the effect of LPS-induced NF-κB activity and its inhibition in DPSCs and PDLSCs. DPSCs and PDLSCs were cultured in an osteogenic medium, pretreated with/without NF-κB inhibitor Bay 11-7082, and treated with/without LPS. Alizarin red staining was performed to assess bone nodule formation, which was observed under an inverted light microscope. NF-κB and alkaline phosphatase (ALP) activities were measured to examine the effect of Bay 11-7082 pretreatment and LPS supplementation on osteogenic differentiation of DPSCs and PDLSCs. LPS significantly induced NF-κB activity (p = 0.000) and reduced ALP activity (p = 0.000), which inhibited bone nodule formation in DPSCs and PDLSCs. Bay 11-7082 inhibited LPS-induced NF-κB activity, and partially maintained ALP activity and osteogenic potency of LPS-supplemented DPSCs and PDLSCs. Thus, inhibition of LPS-induced NF-κB activity can maintain the osteogenic potency of DPSCs and PDLSCs.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Brazilian Oral Research
- Vol. 38, e037
Open AccessInhibition of lipopolysaccharide-induced NF-κB maintains osteogenesis of dental pulp and periodontal ligament stem cells
Dental pulp stem cells (DPSCs) and periodontal ligament stem cells (PDLSCs) can differentiate into osteoblasts, indicating that both are potential candidates for bone tissue engineering. Osteogenesis is influenced by many environmental factors, one of which is lipopolysaccharide (LPS). LPS-induced NF-κB activity affects the osteogenic potencies of different types of MSCs differently. This study evaluated the effect of LPS-induced NF-κB activity and its inhibition in DPSCs and PDLSCs. DPSCs and PDLSCs were cultured in an osteogenic medium, pretreated with/without NF-κB inhibitor Bay 11-7082, and treated with/without LPS. Alizarin red staining was performed to assess bone nodule formation, which was observed under an inverted light microscope. NF-κB and alkaline phosphatase (ALP) activities were measured to examine the effect of Bay 11-7082 pretreatment and LPS supplementation on osteogenic differentiation of DPSCs and PDLSCs. LPS significantly induced NF-κB activity (p = 0.000) and reduced ALP activity (p = 0.000), which inhibited bone nodule formation in DPSCs and PDLSCs. Bay 11-7082 inhibited LPS-induced NF-κB activity, and partially maintained ALP activity and osteogenic potency of LPS-supplemented DPSCs and PDLSCs. Thus, inhibition of LPS-induced NF-κB activity can maintain the osteogenic potency of DPSCs and PDLSCs.
- 18 May 2022
- Published by Springer Nature in Regenerative Engineering and Translational Medicine
- Vol. 8  (4) , 607-614
Effect of Type 2 Diabetes Mellitus Patient’s Serum as Preconditioning on Umbilical Cord Mesenchymal–Derived Secretome Production
- 18 May 2022
- Published by Springer Nature in Regenerative Engineering and Translational Medicine
- Vol. 8  (4) , 607-614
Effect of Type 2 Diabetes Mellitus Patient’s Serum as Preconditioning on Umbilical Cord Mesenchymal–Derived Secretome Production
- Open Access
- 1 April 2022
- Published by Taylor & Francis in Stem Cells and Cloning: Advances and Applications
- Vol. ume 15, 1-9
Interleukins Profiling in Umbilical Cord Mesenchymal Stem Cell-Derived Secretome
Background: Umbilical cord mesenchymal stem cells (UC-MSCs)-derived secretome is currently used in regenerative therapy. MSCs are believed to secrete a wide spectrum of bioactive molecules which give paracrine effects in immunomodulation and regenerative capacities. One group that was found in secretome is interleukins (ILs), a cytokine that plays an essential role in the process of proliferation, differentiation, maturation, migration, and adhesion of immune cells. However, as there are many types of ILs, the profile of ILs in the UC-MSCs-derived secretome has been limitedly reported. Therefore, in this study, we would like to profile and detect the interleukin concentration secreted by UC-MSCs. Methods: UC-MSCs-derived secretome was collected from UC-MSCs passage 5 after 24- and 48-hour incubation (n=9). Secretome was filtered using 0.2 μm and stored at − 80°C for further detection. All samples were normalized before the interleukin (IL-2, IL-4, IL-6, IL-9, IL-10, IL-12, IL-17A) detection using a MACSPlex Cytokine Kit. Results: The IL-6 has the highest concentration among other interleukins in both groups and increases significantly (p< 0.003) after incubation for 48 hours. The pro-inflammatory factors are decreasing while anti-inflammatory factors are increasing after 48-hour incubation. Discussion: Our studies show that the UC-MSCs secrete pro- and anti-inflammatory interleukins. The concentration of anti-inflammatory interleukins shows to be increasing, while the pro-inflammatory interleukins are decreasing within the longer incubation time, but this not be applicable for IL-10 and IL-6. IL-6 has the highest concentration among other ILs. These results may provide important clues regarding when is the right time for secretome to be used in therapy patients, because all the molecules in the secretome can lead to many clinical manifestations.
- 1 April 2022
- Published by Taylor & Francis in Stem Cells and Cloning: Advances and Applications
- Vol. ume 15, 1-9
Open AccessInterleukins Profiling in Umbilical Cord Mesenchymal Stem Cell-Derived Secretome
Background: Umbilical cord mesenchymal stem cells (UC-MSCs)-derived secretome is currently used in regenerative therapy. MSCs are believed to secrete a wide spectrum of bioactive molecules which give paracrine effects in immunomodulation and regenerative capacities. One group that was found in secretome is interleukins (ILs), a cytokine that plays an essential role in the process of proliferation, differentiation, maturation, migration, and adhesion of immune cells. However, as there are many types of ILs, the profile of ILs in the UC-MSCs-derived secretome has been limitedly reported. Therefore, in this study, we would like to profile and detect the interleukin concentration secreted by UC-MSCs. Methods: UC-MSCs-derived secretome was collected from UC-MSCs passage 5 after 24- and 48-hour incubation (n=9). Secretome was filtered using 0.2 μm and stored at − 80°C for further detection. All samples were normalized before the interleukin (IL-2, IL-4, IL-6, IL-9, IL-10, IL-12, IL-17A) detection using a MACSPlex Cytokine Kit. Results: The IL-6 has the highest concentration among other interleukins in both groups and increases significantly (p< 0.003) after incubation for 48 hours. The pro-inflammatory factors are decreasing while anti-inflammatory factors are increasing after 48-hour incubation. Discussion: Our studies show that the UC-MSCs secrete pro- and anti-inflammatory interleukins. The concentration of anti-inflammatory interleukins shows to be increasing, while the pro-inflammatory interleukins are decreasing within the longer incubation time, but this not be applicable for IL-10 and IL-6. IL-6 has the highest concentration among other ILs. These results may provide important clues regarding when is the right time for secretome to be used in therapy patients, because all the molecules in the secretome can lead to many clinical manifestations.
- 7 January 2022
- Published by Springer Nature in Regenerative Engineering and Translational Medicine
- Vol. 8  (3) , 384-393
Factors Influencing the Therapeutic Potential of the MSC-derived Secretome
- 7 January 2022
- Published by Springer Nature in Regenerative Engineering and Translational Medicine
- Vol. 8  (3) , 384-393
Factors Influencing the Therapeutic Potential of the MSC-derived Secretome
- 10 March 2021
- Published by Springer Nature in Regenerative Engineering and Translational Medicine
- Vol. 8  (1) , 43-54
Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19
The COVID-19 disease, which is caused by the novel coronavirus, SARS-CoV-2, has affected the world by increasing the mortality rate in 2020. Currently, there is no definite treatment for COVID-19 patients. Several clinical trials have been proposed to overcome this disease and many are still under investigation. In this review, we will be focusing on the potency of mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. Fever, cough, headache, dizziness, and fatigue are the common clinical manifestations in COVID-19 patients. In mild and severe cases, cytokines are released hyper-actively which causes a cytokine storm leading to acute respiratory distress syndrome (ARDS). In order to maintain the lung microenvironment in COVID-19 patients, MSCs are used as cell-based therapy approaches as they can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote endogenous repair. Besides, MSCs have shown minimal expression of ACE2 or TMPRSS2, and hence, MSCs are free from SARS-CoV-2 infection. Numerous clinical studies have started worldwide and demonstrated that MSCs have great potential for ARDS treatment in COVID-19 patients. Preliminary data have shown that MSCs and MSC-derived secretome appear to be promising in the treatment of COVID-19. Lay Summary The COVID-19 disease is an infection disease which affects the world in 2020. Currently, there is no definite treatment for COVID-19 patients. However, several clinical trials have been proposed to overcome this disease and one of them is using mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. During the infection, cytokines are released hyper-actively which causes a cytokine storm. MSCs play an important role in maintaining the lung microenvironment in COVID-19 patients. They can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote the endogenous repair. Therefore, it is important to explore the clinical trial in the world for treating the COVID-19 disease using MSCs and MSC-derived secretome.
- 10 March 2021
- Published by Springer Nature in Regenerative Engineering and Translational Medicine
- Vol. 8  (1) , 43-54
Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19
The COVID-19 disease, which is caused by the novel coronavirus, SARS-CoV-2, has affected the world by increasing the mortality rate in 2020. Currently, there is no definite treatment for COVID-19 patients. Several clinical trials have been proposed to overcome this disease and many are still under investigation. In this review, we will be focusing on the potency of mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. Fever, cough, headache, dizziness, and fatigue are the common clinical manifestations in COVID-19 patients. In mild and severe cases, cytokines are released hyper-actively which causes a cytokine storm leading to acute respiratory distress syndrome (ARDS). In order to maintain the lung microenvironment in COVID-19 patients, MSCs are used as cell-based therapy approaches as they can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote endogenous repair. Besides, MSCs have shown minimal expression of ACE2 or TMPRSS2, and hence, MSCs are free from SARS-CoV-2 infection. Numerous clinical studies have started worldwide and demonstrated that MSCs have great potential for ARDS treatment in COVID-19 patients. Preliminary data have shown that MSCs and MSC-derived secretome appear to be promising in the treatment of COVID-19. Lay Summary The COVID-19 disease is an infection disease which affects the world in 2020. Currently, there is no definite treatment for COVID-19 patients. However, several clinical trials have been proposed to overcome this disease and one of them is using mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. During the infection, cytokines are released hyper-actively which causes a cytokine storm. MSCs play an important role in maintaining the lung microenvironment in COVID-19 patients. They can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote the endogenous repair. Therefore, it is important to explore the clinical trial in the world for treating the COVID-19 disease using MSCs and MSC-derived secretome.
- Open Access
- 5 June 2020
- Published by F1000 Research Ltd in F1000Research
- Vol. 9, 537
Human umbilical cord blood-mesenchymal stem cell-derived secretome in combination with atorvastatin enhances endothelial progenitor cells proliferation and migration
Background: Human umbilical cord blood-mesenchymal stem cell (hUCB-MSC)-derived secretome is known to be able to promote neovascularization and angiogenesis, so it is also thought to have a capability to modulate endothelial progenitor cell (EPC) functions. Atorvastatin is the cornerstone of coronary artery disease (CAD) treatment which can enhance EPCs proliferation and migration. This study aims to analyze the effect of the hUCB-MSC-derived secretome and its combination with atorvastatin toward EPCs proliferation and migration. Methods: EPCs were isolated from a CAD patient’s peripheral blood. Cultured EPCs were divided into a control group and treatment group of 2.5 µM atorvastatin, hUCB-MSC-derived secretome (2%, 10%, and 20% concentration) and its combination. EPCs proliferation was evaluated using an MTT cell proliferation assay, and EPC migration was evaluated using a Transwell migration assay kit. Results: This research showed that hUCB-MSC-derived secretomes significantly increase EPC proliferation and migration in a dose-dependent manner. The high concentration of hUCB-MSC-derived secretome were shown to be superior to atorvastatin in inducing EPC proliferation and migration (p<0.001). A combination of the hUCB-MSC-derived secretome and atorvastatin shown to improve EPCs proliferation and migration compared to hUCB-MSC-derived secretome treatment or atorvastatin alone (p<0.001). Conclusions: This study concluded that the hUCB-MSC-derived secretome work synergistically with atorvastatin treatment in improving EPCs proliferation and migration.
- 5 June 2020
- Published by F1000 Research Ltd in F1000Research
- Vol. 9, 537
Open AccessHuman umbilical cord blood-mesenchymal stem cell-derived secretome in combination with atorvastatin enhances endothelial progenitor cells proliferation and migration
Background: Human umbilical cord blood-mesenchymal stem cell (hUCB-MSC)-derived secretome is known to be able to promote neovascularization and angiogenesis, so it is also thought to have a capability to modulate endothelial progenitor cell (EPC) functions. Atorvastatin is the cornerstone of coronary artery disease (CAD) treatment which can enhance EPCs proliferation and migration. This study aims to analyze the effect of the hUCB-MSC-derived secretome and its combination with atorvastatin toward EPCs proliferation and migration. Methods: EPCs were isolated from a CAD patient’s peripheral blood. Cultured EPCs were divided into a control group and treatment group of 2.5 µM atorvastatin, hUCB-MSC-derived secretome (2%, 10%, and 20% concentration) and its combination. EPCs proliferation was evaluated using an MTT cell proliferation assay, and EPC migration was evaluated using a Transwell migration assay kit. Results: This research showed that hUCB-MSC-derived secretomes significantly increase EPC proliferation and migration in a dose-dependent manner. The high concentration of hUCB-MSC-derived secretome were shown to be superior to atorvastatin in inducing EPC proliferation and migration (p<0.001). A combination of the hUCB-MSC-derived secretome and atorvastatin shown to improve EPCs proliferation and migration compared to hUCB-MSC-derived secretome treatment or atorvastatin alone (p<0.001). Conclusions: This study concluded that the hUCB-MSC-derived secretome work synergistically with atorvastatin treatment in improving EPCs proliferation and migration.
- 1 May 2020
- Published by Elsevier in Cytotherapy
- Vol. 22  (5) , S196-S197
Quarantine Time Validation for UC-MSC Isolation
- 1 May 2020
- Published by Elsevier in Cytotherapy
- Vol. 22  (5) , S196-S197
Quarantine Time Validation for UC-MSC Isolation
- 1 May 2020
- Published by Elsevier in Cytotherapy
- Vol. 22  (5) , S102
Case Report: Safety profile and efficacy of allogeneic umbilical cord-mesenchymal stem cells therapy via intracoronary route for acute myocardial infarction
- 1 May 2020
- Published by Elsevier in Cytotherapy
- Vol. 22  (5) , S102
Case Report: Safety profile and efficacy of allogeneic umbilical cord-mesenchymal stem cells therapy via intracoronary route for acute myocardial infarction
- 1 May 2020
- Published by Elsevier in Cytotherapy
- Vol. 22  (5) , S75-S76
Basic Fibroblast Growth Factor and Epithelial Growth Factor could Induce Trans-differentiation of Mesenchymal Stem Cell into Neural Stem Cell
- 1 May 2020
- Published by Elsevier in Cytotherapy
- Vol. 22  (5) , S75-S76
Basic Fibroblast Growth Factor and Epithelial Growth Factor could Induce Trans-differentiation of Mesenchymal Stem Cell into Neural Stem Cell